apollomics_logo.png
Apollomics, Inc. Presents Positive Preclinical Data on APL-102, an oral Multi-Kinase Inhibitor with CSF-1R Activity
01 avr. 2019 13h00 HE | Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China, April 01, 2019 (GLOBE NEWSWIRE) -- Apollomics, Inc. (the “Company”), an innovative biopharmaceutical company committed to the discovery and development of...
apollomics_logo.png
Apollomics, Inc.透過任命重要職位以增強領導能力
22 janv. 2019 07h50 HE | CBT Pharmaceuticals
Wilson W. Cheung,CPA獲任命為財務總監Debra L. Thoma Vallner博士,工商管理碩士,獲任命為開發營運部高級副總裁 加利福尼亞州福斯特城和中國杭州, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Apollomics, Inc.是一家致力發現和開發腫瘤組合療法的創新型生物製藥公司,今天宣布任命Wilson W....
apollomics_logo.png
Apollomics,Inc.通过对关键职位的任命加强领导力
22 janv. 2019 07h50 HE | CBT Pharmaceuticals
Wilson W. Cheung,CPA任命其为首席财务官Debra L. Thoma Vallner,博士,工商管理硕士,任命其为开发运营高级副总裁 加利福尼亚州福斯特城和中国杭州, Jan. 22, 2019 (GLOBE NEWSWIRE) -- 致力于发现和开发肿瘤组合疗法的创新型生物制药公司Apollomics,Inc.,今天宣布任命Wilson W. Cheung...
apollomics_logo.png
Apollomics, Inc. Strengthens Leadership with Key Hires
22 janv. 2019 07h50 HE | Apollomics, Inc.
Wilson W. Cheung, CPA appointed Chief Financial OfficerDebra L. Thoma Vallner, PhD, MBA named Senior Vice President, Development Operations FOSTER CITY, Calif. and HANGZHOU, China, Jan. 22, 2019 ...
创新生物制药公司Apollomics完成
创新生物制药公司Apollomics完成1亿美元融资
07 janv. 2019 07h50 HE | CBT Pharmaceuticals
FOSTER CITY, Calif. and HANGZHOU, China, Jan. 07, 2019 (GLOBE NEWSWIRE) --...
apollomics_logo.png
Apollomics, Inc. (previously CBT Pharmaceuticals, Inc.) Raises $100 Million in Series B Financing
07 janv. 2019 07h50 HE | CBT Pharmaceuticals
Financing will accelerate development of the Company’s cancer immunotherapy and targeted therapy programs  New brand reinforces Apollomics’ mission to discover and develop novel medicines and...
cbt_pharma_logo_large_b.png
CBT Pharmaceuticals與Strata Oncology宣佈合作以加快CBT-101的研發。CBT-101是一種高度選擇性的c-Met抑制劑,用於治療非小細胞肺癌及其他實體腫瘤患者
10 déc. 2018 07h50 HE | CBT Pharmaceuticals
美國加利福尼亞州普萊森頓、中國杭州以及美國密歇根州安娜堡, Dec. 10, 2018 (GLOBE NEWSWIRE) -- CBT Pharmaceuticals (CBT) 是一間在中美兩國均設有辦事處的創新醫藥公司,而Strata...
cbt_pharma_logo_large_b.png
CBT Pharmaceuticals和Strata Oncology宣布合作以加快CBT-101的研发。CBT-101是一种高度选择性的c-Met抑制剂,用于治疗非小细胞肺癌及其他实体肿瘤患者
10 déc. 2018 07h50 HE | CBT Pharmaceuticals
美国加利福尼亚州普莱森顿、中国杭州以及美国密歇根州安娜堡, Dec. 10, 2018 (GLOBE NEWSWIRE) -- CBT Pharmaceuticals (CBT), Inc. 是一家在中美两国均设有总部的创新医药公司,而Strata Oncology, Inc....
cbt_pharma_logo_large_b.png
CBT Pharmaceuticals and Strata Oncology Announce Collaboration to Accelerate Development of CBT-101, a c-Met inhibitor, for Patients with Non-Small Cell Lung Cancer and other Solid Tumors
10 déc. 2018 07h50 HE | CBT Pharmaceuticals
PLEASANTON, Calif., HANGZHOU, China and ANN ARBOR, Mich., Dec. 10, 2018 (GLOBE NEWSWIRE) -- CBT Pharmaceuticals (CBT), Inc., a U.S. and China-based innovative pharmaceutical company, and Strata...
cbt_pharma_logo_large_b.png
CBT Pharmaceuticals和Zhejiang Bossan Pharmaceutical簽訂合作和授權協議,共同研發癌症複合療法
26 nov. 2018 07h50 HE | CBT Pharmaceuticals
美國加州普萊森頓和中國杭州, Nov. 26, 2018 (GLOBE NEWSWIRE) -- CBT Pharmaceuticals(CBT)和Zhejiang Bossan Pharmaceutical Co., Ltd...